Background and Aims: In Parkinson's disease (PD), COMT inhibitor (iCOMT) usage extend the elimination half‐life of levodopa and reduce peak‐trough variations, contributing to optimize the dose of levodopa and stabilize plasma levels [1]. Here, COMT is linked to Parkinson disease.